CHANNELS

Subscribe to the InfoTech eNewsletter

infoTECH News

TMCNet:  Research and Markets: Genital Herpes - Pipeline Review, H1 2014: 8 Companies and 13 Drugs Profiled

[May 12, 2014]

Research and Markets: Genital Herpes - Pipeline Review, H1 2014: 8 Companies and 13 Drugs Profiled

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/32tf4h/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-clas products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Genital Herpes
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Genital Herpes and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Genital Herpes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Genital Herpes pipeline on the basis of target, MoA, route of administration and molecule type

Companies Mentioned:

  • Agenus, Inc.
  • AiCuris GmbH & Co. KG
  • Flamel Technologies S.A.
  • Foamix Ltd.
  • NanoViricides, Inc.
  • Profectus BioSciences, Inc.
  • Starpharma Holdings Limited
  • Vical Incorporated

Drug Profiles:

  • acyclovir SR
  • HerpV Vaccine
  • pritelivir
  • astodrimer
  • VCLHB-01
  • VCLHM-01
  • ZEP-3
  • HerpeCide-I
  • HSV-2 Vaccine
  • acyclovir
  • Genital Herpes Vaccine
  • Therapeutic/Prophylactic Vaccine Program For Herpes Simplex Virus
  • Drugs for Bacterial and Viral Infections

For more information visit http://www.researchandmarkets.com/research/32tf4h/genital_herpes


[ InfoTech Spotlight's Homepage ]


blog comments powered by Disqus

FOLLOW US

Subscribe to InfoTECH Spotlight eNews

InfoTECH Spotlight eNews delivers the latest news impacting technology in the IT industry each week. Sign up to receive FREE breaking news today!
FREE eNewsletter